Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Measurement of benign prostatic hyperplasia treatment effects on male sexual function

International Journal of Impotence Research volume 21, pages 267–274 (2009)Cite this article

Abstract

Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms among the aging male population. Epidemiological, pathophysiological and clinical studies indicate that many of these men also suffer from declining sexual function, especially those undergoing treatment for their BPH-related urinary symptoms. Although urinary symptoms and quality of life may improve with BPH therapy, the resulting effects on sexual function vary by medical, surgical and minimally invasive approaches and have not been consistently reported. As comprehensive, validated instruments to measure male sexual function are now available for routine use in the clinical setting, urologists and primary care providers caring for patients with BPH have the opportunity to monitor both urinary and sexual function before, during and after BPH therapy. Herein, we describe the relationship between BPH and its treatments on male sexual function, the role of new measures for sexual functioning and opportunities for future work to improve the care of men suffering from both maladies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  2. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436–442.

    CAS  PubMed  Google Scholar 

  3. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    CAS  PubMed  Google Scholar 

  4. Melman A, Gingell JC . The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161: 5–11.

    CAS  PubMed  Google Scholar 

  5. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R et al. The prevalence of male urinary incontinence in four centres: the UREPIK study. BJU Int 2003; 92: 943–947.

    CAS  PubMed  Google Scholar 

  6. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I . The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998; 82: 842–846.

    CAS  PubMed  Google Scholar 

  7. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    CAS  PubMed  Google Scholar 

  8. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH . Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘Aging Male’ symptoms? Results of the ‘Cologne Male Survey’. Eur Urol 2003; 44: 588–594.

    CAS  PubMed  Google Scholar 

  9. Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int 2008; 101: 197–202.

    PubMed  Google Scholar 

  10. McVary KT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.

    PubMed  Google Scholar 

  11. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    PubMed  Google Scholar 

  12. Chung WS, Nehra A, Jacobson DJ, Roberts RO, Rhodes T, Girman CJ et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc 2004; 79: 745–749.

    PubMed  Google Scholar 

  13. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM . Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277–284.

    CAS  PubMed  Google Scholar 

  14. Welch G, Weinger K, Barry MJ . Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245–250.

    PubMed  Google Scholar 

  15. Carbone Jr DJ, Hodges S . Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299–306.

    PubMed  Google Scholar 

  16. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170 (2 Pt 1): 530–547.

    Google Scholar 

  17. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int 2003; 92: 575–580.

    CAS  PubMed  Google Scholar 

  18. O'Leary MP, Wei JT, Roehrborn CG, Miner M . Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int 2008; 101: 1531–1535.

    PubMed  Google Scholar 

  19. Barry MJ . Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001; 58 (6 Suppl 1): 25–32; discussion 32.

    CAS  PubMed  Google Scholar 

  20. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557; discussion 1564.

    CAS  PubMed  Google Scholar 

  21. Batista-Miranda JE, Diez MD, Bertran PA, Villavicencio H . Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. Pharmacoeconomics 2001; 19: 1079–1090.

    CAS  PubMed  Google Scholar 

  22. Cockett A, Aso Y, Denis L . Prostate symptom score and quality of life assessment. In: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds). Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH); 27–30 June 1993. Paris; Channel Island, Jersey: Scientific Communication International, 1994, pp 553–555.

    Google Scholar 

  23. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  PubMed  Google Scholar 

  24. Panser LA, Rhodes T, Girman CJ, Guess HA, Chute CG, Oesterling JE et al. Sexual function of men ages 40–79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc 1995; 43: 1107–1111.

    CAS  PubMed  Google Scholar 

  25. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P . Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991; 337: 1457–1461.

    CAS  PubMed  Google Scholar 

  26. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467–1474.

    CAS  PubMed  Google Scholar 

  27. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P . Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 155–167.

    CAS  PubMed  Google Scholar 

  28. Abrams P, Schulman CC, Vaage S . Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995; 76: 325–336.

    CAS  PubMed  Google Scholar 

  29. Roehrborn CG, Siegel RL . Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406–415.

    CAS  PubMed  Google Scholar 

  30. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–1191.

    CAS  PubMed  Google Scholar 

  31. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533–539.

    CAS  PubMed  Google Scholar 

  32. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34: 169–175.

    CAS  PubMed  Google Scholar 

  33. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    CAS  PubMed  Google Scholar 

  34. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY . Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin Ther 1995; 17: 956–969.

    CAS  PubMed  Google Scholar 

  35. Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ, Wang C et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 2008; 179: 2333–2338.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Rosen RC, Giuliano F, Carson CC . Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824–837.

    PubMed  Google Scholar 

  37. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5–alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–441.

    PubMed  Google Scholar 

  38. Roehrborn CG, Rosen RC . Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging 2008; 3: 511–524.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Chung BH, Lee JY, Kim CI, Kim CS, Oh CY, Lee SW et al. Sexuality and the management of BPH with alfuzosin (SAMBA) trial. Int J Impot Res 2009; 21: 68–73.

    PubMed  Google Scholar 

  40. Kaplan SA, AF DER, Kirby RS, O'Leary M P, McVary KT . Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU Int 2006; 97: 559–566.

    CAS  PubMed  Google Scholar 

  41. Lowe FC . Role of the newer alpha-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004; 26: 1701–1713.

    CAS  PubMed  Google Scholar 

  42. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47: 159–168.

    CAS  PubMed  Google Scholar 

  43. Lepor H . Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892–900.

    CAS  PubMed  Google Scholar 

  44. Hofner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ . Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–341.

    CAS  PubMed  Google Scholar 

  45. Lapitan MC, Acepcion V, Mangubat J . A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. J Int Med Res 2005; 33: 562–573.

    CAS  PubMed  Google Scholar 

  46. Hellstrom WJ, Sikka SC . Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176 (4 Pt 1): 1529–1533.

    CAS  PubMed  Google Scholar 

  47. Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J . A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 605–608.

    CAS  PubMed  Google Scholar 

  48. Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1–adrenoceptors and native tissues. Mol Pharmacol 1995; 48: 250–258.

    CAS  PubMed  Google Scholar 

  49. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G . Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634–2640.

    CAS  PubMed  Google Scholar 

  50. Yono M, Yamamoto Y, Imanishi A, Fukagawa A, Latifpour J, Yoshida M . Short- and long-term effects of silodosin, a selective alpha-adrenoceptor antagonist, on ejaculatory function in rats. BJU Int 2009; 103: 1680–1685.

    CAS  PubMed  Google Scholar 

  51. Kobayashi K, Masumori N, Hisasue S, Kato R, Hashimoto K, Itoh N et al. Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med 2008; 5: 2185–2190.

    PubMed  Google Scholar 

  52. AUA Practice Guidelines Committee. AUA Guideline on Management of Benign Prostatic Hyperplasia, Chapter 3: Results of the Treatment Outcomes Analyses. American Urological Association: Linthincum, MD, 2003, pp 56.

  53. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA . Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009; 73: 562–566.

    PubMed  Google Scholar 

  54. Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000; 164: 1206–1211.

    CAS  PubMed  Google Scholar 

  55. Finkle AL, Moyers TG . Sexual potency in aging males. IV. Status of private patients before and after prostatectomy. J Urol 1960; 84: 152–157.

    CAS  PubMed  Google Scholar 

  56. Schulman C . Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 2001; 4 (S1): S12–S16.

    CAS  PubMed  Google Scholar 

  57. Fowler Jr FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley Jr AG, Hanley D . Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 3018–3022.

    PubMed  Google Scholar 

  58. Kinn AC, Helmy-Dhejne C, Larsson J . Sexual function one year after transurethral prostatic resection. Patients' own assessments. Scand J Urol Nephrol 1998; 32: 33–35.

    CAS  PubMed  Google Scholar 

  59. Cimentepe E, Unsal A, Saglam R . Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003; 17: 103–107.

    PubMed  Google Scholar 

  60. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD . Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777–782.

    PubMed  Google Scholar 

  61. Hargreave TB, Stephenson TP . Potency and prostatectomy. Br J Urol 1977; 49: 683–688.

    CAS  PubMed  Google Scholar 

  62. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM . Development and evaluation of an abridged, 5–item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

    CAS  PubMed  Google Scholar 

  63. Rosen RC, Catania JA, Althof SE, Pollack LM, O'Leary M, Seftel AD et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 2007; 69: 805–809.

    PubMed  Google Scholar 

  64. McVary K . Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97 (Suppl 2): 23–28; discussion 44–25.

    PubMed  Google Scholar 

  65. Roehrborn CG . Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004; 6: 121–127.

    PubMed  PubMed Central  Google Scholar 

  66. Kaplan SA, Gonzalez RR . Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 2007; 9: 73–77.

    PubMed  PubMed Central  Google Scholar 

  67. Master VA, Turek PJ . Ejaculatory physiology and dysfunction. Urol Clin North Am 2001; 28: 363–375, x.

    CAS  PubMed  Google Scholar 

  68. Lynch M, Anson K . Time to rebrand transurethral resection of the prostate? Curr Opin Urol 2006; 16: 20–24.

    PubMed  Google Scholar 

  69. Doll HA, Black NA, McPherson K, Williams GB, Smith JC . Differences in outcome of transurethral resection of the prostate for benign prostatic hypertrophy between three diagnostic categories. Br J Urol 1993; 72: 322–330.

    CAS  PubMed  Google Scholar 

  70. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG . A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332: 75–79.

    CAS  PubMed  Google Scholar 

  71. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA . Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther 1997; 19: 243–258.

    CAS  PubMed  Google Scholar 

  72. Seftel A, Rosen R, Kuritzky L . Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007; 19: 386–392.

    CAS  PubMed  Google Scholar 

  73. Roehrborn CG, Nuckolls JG, Wei JT, Steers W . The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int 2007; 100: 813–819.

    PubMed  Google Scholar 

  74. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ . A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762–774.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. De Rose AF, Carmignani G, Corbu C, Giglio M, Traverso P, Naselli A et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95–98.

    CAS  PubMed  Google Scholar 

  76. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119–126.

    PubMed  Google Scholar 

  77. Chapple CR . A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol 2005; 7 (Suppl 4): S22–S30.

    PubMed  PubMed Central  Google Scholar 

  78. Roehrborn CG, Van Kerrebroeck P, Nordling J . Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257–261.

    CAS  PubMed  Google Scholar 

  79. Narayan P, Lepor H . Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466–470.

    CAS  PubMed  Google Scholar 

  80. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ . Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999; 36: 609–620.

    CAS  PubMed  Google Scholar 

  81. Prescribing information. Flomax (tamsulosin hydrochloride) capsules. Physicians' Desk Reference. 55th edn Medical Economics Company: Montvale, NJ, 2002, pp 974–977.

  82. Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y . Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008; 15: 915–918.

    PubMed  Google Scholar 

  83. Kawabe K, Yoshida M, Homma Y . Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98: 1019–1024.

    CAS  PubMed  Google Scholar 

  84. Kaminetsky J . Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 2006; 22: 2497–2506.

    PubMed  Google Scholar 

  85. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557–563.

    CAS  PubMed  Google Scholar 

  86. Marberger MJ . Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677–686.

    CAS  PubMed  Google Scholar 

  87. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2–year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Cmaj 1996; 155: 1251–1259.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS . Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 1323–1328.

    CAS  PubMed  Google Scholar 

  89. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K . Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 262–266.

    CAS  PubMed  Google Scholar 

  90. Marihart S, Harik M, Djavan B . Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol 2005; 7: 203–210.

    PubMed  PubMed Central  Google Scholar 

  91. Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR . Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997; 80: 579–586.

    CAS  PubMed  Google Scholar 

  92. Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588–1593; discussion 1593–1584.

    CAS  PubMed  Google Scholar 

  93. Steele GS, Sleep DJ . Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 1997; 158: 1834–1838.

    CAS  PubMed  Google Scholar 

  94. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC . Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89–93.

    PubMed  Google Scholar 

  95. Miner M, Rosenberg MT, Perelman MA . Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006; 28: 13–25.

    PubMed  Google Scholar 

  96. Guazzoni G, Montorsi F, Coulange C, Milroy E, Pansadoro V, Rubben H et al. A modified prostatic UroLume Wallstent for healthy patients with symptomatic benign prostatic hyperplasia: a European Multicenter Study. Urology 1994; 44: 364–370.

    CAS  PubMed  Google Scholar 

  97. Roehrborn CG . The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 445–453.

    CAS  PubMed  Google Scholar 

  98. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE . Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. Br Med J 2002; 324: 1059–1061.

    Google Scholar 

  99. Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC . Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45: 768–775.

    CAS  PubMed  Google Scholar 

  100. Hoffman RM, MacDonald R, Wilt TJ . Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004 CD001987.

Download references

Acknowledgements

This study was supported by an NIH T32 training grant (NIH 2 T32 DK007782-06).

Author information

Authors and Affiliations

  1. Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA

    T A Skolarus & J T Wei

Authors
  1. T A Skolarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J T Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J T Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skolarus, T., Wei, J. Measurement of benign prostatic hyperplasia treatment effects on male sexual function. Int J Impot Res 21, 267–274 (2009). https://doi.org/10.1038/ijir.2009.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.26

Keywords

Search

Advanced search

Quick links